Who should not take pioglitazone

Who should not use pioglitazone? Allergies to Ingredients. People who are allergic to any of the following should not take pioglitazone. Pioglitazone; Actos; Any other medicine that contains

The safety and efficacy of pioglitazone should be reviewed after 3 6 months and pioglitazone should be stopped in patients who do not respond adequately to treatment. Patients already receiving treatment with pioglitazone should be assessed for risk factors of bladder cancer and treatment should be reviewed after 3 6 months, as above.

The safety and efficacy of pioglitazone should be reviewed after 3 6 months and pioglitazone should be stopped in patients who do not respond adequately to treatment. Patients already receiving treatment with pioglitazone should be assessed for risk factors of bladder cancer and treatment should be reviewed after 3 6 months, as above.

Is there a certain diet I should follow while taking pioglitazone? Is there a best time of day to take my pioglitazone dose? nbsp;Article

Pioglitazone tablets are not for people with diabetic ketoacidosis (increased ketones in your blood or urine). Who should not take pioglitazone tablets? See Wha t is the most important information I should know about pioglitazone tablets? Do not take pioglitazone tablets if you: have severe heart failure

The safety and efficacy of pioglitazone should be reviewed after 3 6 months and pioglitazone should be stopped in patients who do not respond adequately to treatment. Patients already receiving treatment with pioglitazone should be assessed for risk factors of bladder cancer and treatment should be reviewed after 3 6 months, as above.

Patients who take pioglitazone should be closely monitored for signs of heart failure; treatment should be discontinued if any deterioration in cardiac status occurs. Pioglitazone should not be used in patients with heart failure or a history of heart failure. Pioglitazone: risk of bladder cancer (July 2024)

Patients who have liver test abnormalities prior to initiation of pioglitazone tablets or who are found to have abnormal liver tests while taking pioglitazone tablets should be managed as described under Warnings and Precautions [see Warnings and Precautions (5.3)and Clinical Pharmacology (12.3)].

The safety and efficacy of pioglitazone should be reviewed after 3 6 months and pioglitazone should be stopped in patients who do not respond adequately to treatment. Patients already receiving treatment with pioglitazone should be assessed for risk factors of bladder cancer and treatment should be reviewed after 3 6 months, as above.